Cullinan Therapeutics logo

Cullinan Therapeutics Share Price Today

(NASDAQ: CGEM)

Cullinan Therapeutics share price is $8.43 & ₹733.15 as on 6 Mar 2025, 2.30 'hrs' IST

$8.43

0.3

(3.69%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Cullinan Therapeutics share price in Dollar and Rupees. Guide to invest in Cullinan Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cullinan Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Cullinan Therapeutics share price movements

  • Today's Low: $8.06
    Today's High: $8.53

    Day's Volatility :5.51%

  • 52 Weeks Low: $7.90
    52 Weeks High: $30.19

    52 Weeks Volatility :73.83%

Cullinan Therapeutics (CGEM) Returns

PeriodCullinan Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-32.23%
3.7%
0.0%
6 Months
-52.98%
-2.8%
0.0%
1 Year
-52.59%
2.5%
0.0%
3 Years
-36.47%
12.9%
-11.6%

Cullinan Therapeutics (CGEM) Key Statistics

in dollars & INR

Previous Close
$8.13
Open
$8.26
Today's High
$8.53
Today's Low
$8.06
Market Capitalization
$475.7M
Today's Volume
$313.5K
52 Week High
$30.1886
52 Week Low
$7.9
Revenue TTM
$0.0
EBITDA
$-196.6M
Earnings Per Share (EPS)
$-2.83
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-32.1%

How to invest in Cullinan Therapeutics Stock (CGEM) from India?

It is very easy for Indian residents to invest directly in Cullinan Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cullinan Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cullinan Therapeutics or CGEM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cullinan Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cullinan Therapeutics shares which would translate to 0.103 fractional shares of Cullinan Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cullinan Therapeutics, in just a few clicks!

Returns in Cullinan Therapeutics (CGEM) for Indian investors in Rupees

The Cullinan Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cullinan Therapeutics investment value today

Current value as on today

₹52,362

Returns

₹47,638

(-47.64%)

Returns from Cullinan Therapeutics Stock

₹52,587 (-52.59%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Cullinan Therapeutics (CGEM)

-33%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Cullinan Therapeutics Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cullinan Therapeutics

  • MPM Oncology Impact Management LP

    13.07%

  • Bvf Inc

    9.83%

  • BlackRock Inc

    7.47%

  • Deerfield Management Co

    5.78%

  • Vanguard Group Inc

    5.02%

  • Citadel Advisors Llc

    4.59%

Analyst Recommendation on Cullinan Therapeutics

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Cullinan Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
11
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Cullinan Therapeutics Stock (CGEM)

What analysts predicted

Upside of 288.82%

Target:

$32.78

Current:

$8.43

Insights on Cullinan Therapeutics Stock (Ticker Symbol: CGEM)

  • Price Movement

    In the last 6 months, CGEM stock has moved down by -53.1%
  • CGEM vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 119.1%
  • CGEM vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 86.4%

Cullinan Therapeutics Technicals Summary

Sell

Neutral

Buy

Cullinan Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Cullinan Therapeutics (CGEM) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cullinan Therapeutics  Inc logo
-17.35%
-52.98%
-52.59%
-36.47%
-71.82%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cullinan Therapeutics  Inc logo
9.03
NA
NA
-3.36
-0.32
-0.22
NA
10.09
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cullinan Therapeutics  Inc logo
Buy
$475.7M
-71.82%
9.03
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Cullinan Therapeutics

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Organization
Cullinan Therapeutics
Employees
111
CEO
Mr. Nadim Ahmed
Industry
Other Consumer Services

Management People of Cullinan Therapeutics

NameTitle
Mr. Nadim Ahmed
President, CEO & Director
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.
Chief Medical Officer
Dr. Patrick A. Baeuerle Ph.D.
Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Dr. Jennifer Michaelson Ph.D.
Chief Scientific Officer
Ms. Jacquelyn L. Sumer J.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Mr. Steve Andre
Chief Human Resources Officer
Dr. Corinne Savill Ph.D.
Chief Business Officer
Ms. Rose Weldon
Senior Vice President of Corporate Affairs
Mr. Kevin A. Johnston
Chief Technical Operations Officer

Important FAQs about investing in CGEM Stock from India :

What is Cullinan Therapeutics share price today?

Cullinan Therapeutics share price today stands at $8.43, Open: $8.26 ; Previous Close: $8.13 ; High: $8.53 ; Low: $8.06 ; 52 Week High: $30.19 ; 52 Week Low: $7.90.

The stock opens at $8.26, after a previous close of $8.13. The stock reached a daily high of $8.53 and a low of $8.06, with a 52-week high of $30.19 and a 52-week low of $7.90.

Can Indians buy Cullinan Therapeutics shares?

Yes, Indians can invest in the Cullinan Therapeutics (CGEM) from India.

With INDmoney, you can buy Cullinan Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cullinan Therapeutics at zero transaction cost.

How can I buy Cullinan Therapeutics shares from India?

It is very easy to buy Cullinan Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cullinan Therapeutics (CGEM) be purchased?

Yes, you can buy fractional shares of Cullinan Therapeutics with INDmoney app.

What are the documents required to start investing in Cullinan Therapeutics stocks?

To start investing in Cullinan Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cullinan Therapeutics Stock (CGEM)?

Today’s highest price of Cullinan Therapeutics (CGEM) is $8.53.

Today’s lowest price of Cullinan Therapeutics (CGEM) is $8.06.

What is today's market capitalisation of Cullinan Therapeutics?

Today's market capitalisation of Cullinan Therapeutics CGEM is 475.7M

What is the 52 Week High and Low Range of Cullinan Therapeutics Stock (CGEM)?

  • 52 Week High

    $30.19

  • 52 Week Low

    $7.90

What are the historical returns of Cullinan Therapeutics (CGEM)?

  • 1 Month Returns

    -17.35%

  • 3 Months Returns

    -52.98%

  • 1 Year Returns

    -52.59%

  • 5 Years Returns

    -71.82%

Who is the Chief Executive Officer (CEO) of Cullinan Therapeutics ?

Mr. Nadim Ahmed is the current Chief Executive Officer (CEO) of Cullinan Therapeutics.